419 related articles for article (PubMed ID: 27166190)
1. Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease.
Szelag M; Piaszyk-Borychowska A; Plens-Galaska M; Wesoly J; Bluyssen HA
Oncotarget; 2016 Jul; 7(30):48788-48812. PubMed ID: 27166190
[TBL] [Abstract][Full Text] [Related]
2. Genome-Wide Inhibition of Pro-atherogenic Gene Expression by Multi-STAT Targeting Compounds as a Novel Treatment Strategy of CVDs.
Plens-Galaska M; Szelag M; Collado A; Marques P; Vallejo S; Ramos-González M; Wesoly J; Sanz MJ; Peiró C; Bluyssen HAR
Front Immunol; 2018; 9():2141. PubMed ID: 30283459
[TBL] [Abstract][Full Text] [Related]
3. Comparative screening and validation as a novel tool to identify STAT-specific inhibitors.
Szeląg M; Czerwoniec A; Wesoly J; Bluyssen HA
Eur J Pharmacol; 2014 Oct; 740():417-20. PubMed ID: 25183399
[TBL] [Abstract][Full Text] [Related]
4. Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation.
Szelag M; Czerwoniec A; Wesoly J; Bluyssen HA
PLoS One; 2015; 10(2):e0116688. PubMed ID: 25710482
[TBL] [Abstract][Full Text] [Related]
5. Direct Inhibition of IRF-Dependent Transcriptional Regulatory Mechanisms Associated With Disease.
Antonczyk A; Krist B; Sajek M; Michalska A; Piaszyk-Borychowska A; Plens-Galaska M; Wesoly J; Bluyssen HAR
Front Immunol; 2019; 10():1176. PubMed ID: 31178872
[TBL] [Abstract][Full Text] [Related]
6. STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease.
Sikorski K; Czerwoniec A; Bujnicki JM; Wesoly J; Bluyssen HA
Cytokine Growth Factor Rev; 2011 Aug; 22(4):211-9. PubMed ID: 21752694
[TBL] [Abstract][Full Text] [Related]
7. In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity.
Szelag M; Sikorski K; Czerwoniec A; Szatkowska K; Wesoly J; Bluyssen HA
Eur J Pharmacol; 2013 Nov; 720(1-3):38-48. PubMed ID: 24211327
[TBL] [Abstract][Full Text] [Related]
8. Suppressor of cytokine signaling 1-derived peptide inhibits Janus kinase/signal transducers and activators of transcription pathway and improves inflammation and atherosclerosis in diabetic mice.
Recio C; Oguiza A; Lazaro I; Mallavia B; Egido J; Gomez-Guerrero C
Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):1953-60. PubMed ID: 25012131
[TBL] [Abstract][Full Text] [Related]
9. "Activated" STAT proteins: a paradoxical consequence of inhibited JAK-STAT signaling in cytomegalovirus-infected cells.
Trilling M; Le VT; Rashidi-Alavijeh J; Katschinski B; Scheller J; Rose-John S; Androsiac GE; Jonjic S; Poli V; Pfeffer K; Hengel H
J Immunol; 2014 Jan; 192(1):447-58. PubMed ID: 24319264
[TBL] [Abstract][Full Text] [Related]
10. STAT1 and IRF8 in Vascular Inflammation and Cardiovascular Disease: Diagnostic and Therapeutic Potential.
Chmielewski S; Piaszyk-Borychowska A; Wesoly J; Bluyssen HA
Int Rev Immunol; 2016 Sep; 35(5):434-454. PubMed ID: 26606328
[TBL] [Abstract][Full Text] [Related]
11. IRF and STAT Transcription Factors - From Basic Biology to Roles in Infection, Protective Immunity, and Primary Immunodeficiencies.
Mogensen TH
Front Immunol; 2018; 9():3047. PubMed ID: 30671054
[TBL] [Abstract][Full Text] [Related]
12. Bacterial ligand of TLR2 signals Stat activation via induction of IRF1/2 and interferon-alpha production.
Liljeroos M; Vuolteenaho R; Rounioja S; Henriques-Normark B; Hallman M; Ojaniemi M
Cell Signal; 2008 Oct; 20(10):1873-81. PubMed ID: 18652890
[TBL] [Abstract][Full Text] [Related]
13. The Molecular Basis of Viral Inhibition of IRF- and STAT-Dependent Immune Responses.
Chiang HS; Liu HM
Front Immunol; 2018; 9():3086. PubMed ID: 30671058
[TBL] [Abstract][Full Text] [Related]
14. Data mining of atherosclerotic plaque transcriptomes predicts STAT1-dependent inflammatory signal integration in vascular disease.
Sikorski K; Wesoly J; Bluyssen HA
Int J Mol Sci; 2014 Aug; 15(8):14313-31. PubMed ID: 25196434
[TBL] [Abstract][Full Text] [Related]
15. STAT1-dependent signal integration between IFNγ and TLR4 in vascular cells reflect pro-atherogenic responses in human atherosclerosis.
Chmielewski S; Olejnik A; Sikorski K; Pelisek J; Błaszczyk K; Aoqui C; Nowicka H; Zernecke A; Heemann U; Wesoly J; Baumann M; Bluyssen HA
PLoS One; 2014; 9(12):e113318. PubMed ID: 25478796
[TBL] [Abstract][Full Text] [Related]
16. Suppressors of cytokine signaling modulate JAK/STAT-mediated cell responses during atherosclerosis.
Ortiz-Muñoz G; Martin-Ventura JL; Hernandez-Vargas P; Mallavia B; Lopez-Parra V; Lopez-Franco O; Muñoz-Garcia B; Fernandez-Vizarra P; Ortega L; Egido J; Gomez-Guerrero C
Arterioscler Thromb Vasc Biol; 2009 Apr; 29(4):525-31. PubMed ID: 19164812
[TBL] [Abstract][Full Text] [Related]
17. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
18. JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin.
Wang X; Liu Q; Ihsan A; Huang L; Dai M; Hao H; Cheng G; Liu Z; Wang Y; Yuan Z
Toxicol Sci; 2012 Jun; 127(2):412-24. PubMed ID: 22454431
[TBL] [Abstract][Full Text] [Related]
19. The role of the growth hormone (GH) receptor and JAK1 and JAK2 kinases in the activation of Stats 1, 3, and 5 by GH.
Smit LS; Meyer DJ; Billestrup N; Norstedt G; Schwartz J; Carter-Su C
Mol Endocrinol; 1996 May; 10(5):519-33. PubMed ID: 8732683
[TBL] [Abstract][Full Text] [Related]
20. Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C.
Radaeva S; Jaruga B; Kim WH; Heller T; Liang TJ; Gao B
Biochem J; 2004 Apr; 379(Pt 1):199-208. PubMed ID: 14690454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
